Amicus Therapeutics is an international biotechnology company based in Cranbury, New Jersey. The firm takes the lead in advanced treatments for a variety of rare and overwhelming illnesses particularly known as lysosomal storage disorders. It has a healthy expansion pipeline of cures for a range of human inherited diseases. The patients’ needs in rare illnesses are at the forefront of clinical programs, innovative science and commercial organizations of Amicus Therapeutics.
The company overall goal in all ranks is to contribute to a meaningful change in the lives of caregivers and their patients through the expertise of the brilliant team. Amicus Therapeutics invests in programs which have to encompass these three main characteristics:
- The ability of the technology to lead the class.
- Provision of meaningful help to patients through clinical data.
- Exist in rare sicknesses of the overwhelming condition.
Amicus Therapeutics Product Development
Amicus Therapeutics product development, built mainly on the Chaperone-Advanced Replacement Therapy (CHART) manifesto has focused on the creation of enzyme replacement. Through CHART, the company has developed several products to counter hereditary diseases like Pompe disease, the Lysosomal Storage Disorders Fabry disease and the genetic connective skin disorder Epidermolysis Bullosa (EB). Migalastat the lead product is a tailored drug in late-stage development to cure persons with Fabry diseases. SD- 101 also at its last stage development is a prospective product which is new in the market, invented to cure rare genetic connective tissue disorder Epidermolysis Bullosa (EB). View the market summary of Amicus Therapeutics at marketwatch.com.
Amicus Therapeutics relate to patients’ diseases and struggles through practicing personal and direct connections with them. Dedication to patients matches their commitment to compliance and ethics, and strive to meet the highest standards of safety and professionalism. They deliver meaningful benefits to patients through business strategies and scientific innovations. The employees at Amicus Therapeutics commits to company vision and continuous skills development. Visit Yahoo Finance to learn more about Amicus Therapeutics.